Abivax S.A. Stock
Price
Target price
€109.00
€109.00
5.610%
5.8
5.610%
-
22:26 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
Abivax S.A. dominated the market today, gaining €5.80 (5.610%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Abivax S.A. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Abivax S.A. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | 5.610% | - | - | - | - | - | - |
| Valneva SE | 1.650% | -2.642% | -8.117% | 84.759% | 76.266% | -43.335% | -35.980% |
| Nanobiotix | 1.820% | -0.667% | 5.059% | 426.223% | 506.658% | 366.928% | 55.304% |
| Transgene S.A. | -2.360% | -1.195% | -4.247% | 62.092% | 81.022% | -30.259% | -21.914% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data